Introduction {#s1}
============

We recently showed the pro-angiogenic functions in tumor development for annexin A1 [@pone.0043551-Yi1] which was previously known as an inflammatory protein. Tumor growth and metastasis were significantly decreased when tumors grew in host animals unable to express annexin A1 [@pone.0043551-Yi1]. While tumor is a piece of heterogeneous mass including not only malignant tumor cells but also the stroma, the importance of the tumor stroma for tumor progression and metastasis is becoming increasingly clear. The tumor stroma is comprised by extracellular matrix and non-malignant cells in the tumor, which include endothelial cells, fibroblasts, immune cells, inflammatory cells such as macrophages [@pone.0043551-Hiscox1], [@pone.0043551-Ahmed1]. Although the tumor stroma has been sought after as a therapeutic target, the mechanisms for how the interaction of various components in the complex tumor stroma contributes to the tumor development are still poorly understood. Based on our recent finding of pro-angiogenic functions for annexin A1 in vascular endothelial cell sprouting, wound healing, and tumor growth and metastasis [@pone.0043551-Yi1], and the previously known properties for annexin A1 in immune cells and inflammation [@pone.0043551-Perretti1], this study hypothesized that annexin A1 is a key functional player in tumor development, linking the various components in tumor stroma by its actions in endothelial cells and immune cells. Here, we used systems biology approach to analyze the tumors in whole animal models on the background of absence or presence of annexin A1 to show the global effects of annexin A1 on tumor stroma. It is impossible to study tumor stroma with isolated proteins, cultured cell homogenates or even whole live cells. Tumor cells in culture lack the microenvironment or the stroma provided by the body that hosts the tumor. Our whole animal models offered significant advantages over any other conditions. Of particular importance our systems based approaches provided thorough analysis and generated interesting and thought-provoking results.

Methods {#s2}
=======

Mice and Tumor Models {#s2a}
---------------------

Annexin A1 knockout homozygous and congenic wildtype counterpart homozygous mice, tumor cell culture, B16 melanoma cell line and subcutaneous tumor model were as described previously [@pone.0043551-Yi1]. Briefly, to grow the xenograft tumors on the mice, B16 melanoma cells were grown in continuous culture for no more than 3 consecutive passages, the actively growing cells were then trypsinized (0.25% trypsin/1 mM Na-EDTA; Gibco/BRL), resuspended in DMEM (Dulbecco modified Eagle medium), counted, and injected subcutaneously into the right flanks of the mice at 5×10^6^ cells in 200 µL DMEM for each mouse. The B16 cell line was an established cell line and was obtained and used in Dr. Schnitzer\'s lab in Sidney Kimmel Cancer Center and Proteogenomics Research Institute for Systems Medicine, San Diego, California, United States of America, and the B16 cell line related work was previously published [@pone.0043551-Yi1].

Systems Analysis and Gene Microarray {#s2b}
------------------------------------

The GeneChip mouse genome 430 2.0 array (Affymetrix) was used to analyze tumors from annexin A1 knockout or wildtype mice as described previously [@pone.0043551-Yi1]. The dataset containing genes that are differentially expressed in the tumors from annexin A1 knockout mice and wildtype mice was analyzed using Genomatix software (Genomatix Software) and Gene Ontology database [@pone.0043551-Ashburner1] and IPA software (Ingenuity Systems).

Study Approval. This study was approved by Sidney Kimmel Cancer Center and Proteogenomics Research Institute for Systems Medicine, San Diego, California, United States of America.

Results {#s3}
=======

The tumors were grown in both annexin A1 null and wild type mice using B16 melanoma cells as described previously [@pone.0043551-Yi1]. In this system, only the stroma in the tumor differs because the non-tumor cells are from the host body with or without annexin A1. From the raw data obtained previously [@pone.0043551-Yi1] using mouse whole genome microarrays to run tumor samples from annexin A1 knockout and wildtype mice, this study performed thorough systems analysis. The gene expression levels in the whole tumors from annexin A1 knockout and wildtype mice were analyzed to obtain differential expression profiling ([Fig. 1](#pone-0043551-g001){ref-type="fig"}). For each gene probe in the mouse genome, the expression levels of the gene probe in tumors from annexin A1 null mice (ko) and from annexin A1 wild-type mice (wt) were compared and expressed as ratio of ko over wt, which reflects from three independent repeat experiments. In tumors from annexin A1 null mice, those genes with highest values were over-expressed (red colored region in [Fig. 1](#pone-0043551-g001){ref-type="fig"}) while those genes with lowest values were under-expressed (blue colored region in [Fig. 1](#pone-0043551-g001){ref-type="fig"}). The majority of the genome was expressed at similar extent in tumors from annexin A1 null and wild-type mice with the expression ratio values approaching one or the logarithm of the expression ratio values close to zero ([Fig. 1](#pone-0043551-g001){ref-type="fig"}). Total about 1000 genes with either highest or lowest ratio values were identified as significantly changed genes in the tumors.

![Gene differential expression profile of tumors from annexin A1 knockout and wild type mice.\
B16 melanoma cells were implanted in annexin A1 knockout and wild type mice to grow up tumors. Whole tumors were analyzed using mouse whole genome microarray, in which for each gene, one or more than one probeset(s) were spotted for the gene. For each probeset on the microarray, the difference in gene expression between tumors from annexin A1 knockout mice and from wild type mice was expressed as log 2 ratio of the gene expression level in annexin A1 knockout (ko) over the gene expression level in wild type (wt).](pone.0043551.g001){#pone-0043551-g001}

We then analyzed this list of significantly changed genes/proteins in a systems biology approach with Genomatix and IPA software to reveal the functional connection with annexin A1. The data were examined in terms of biological processes category, which are the Gene Ontology (GO) structured networks of defined terms to describe gene product attributes. The data were statistically analyzed and expressed as the z-score of a term to check for over- or under- represented groups of genes. Integrated statistical rating allows for the identification and selection of clusters of functionally related genes. All the biological processes in the GO database were obtained from top of the hierarchial tree to further mining down of subcategories of each branch levels by levels. The top most general biological processes are shown with their z-scores ([Fig. 2](#pone-0043551-g002){ref-type="fig"}). Interestingly, most of the biological processes were positively enriched, suggesting that annexin A1 may act as a global regulator which affects many biological processes and some of these processes may balance each other to result in minimum changes, which could contribute to the annexin A1 knockout mice appearing normal overall. The z-score of a term shows whether a certain gene, or group of genes, is over- or under-represented in the set of the genes being analyzed. Among the total 22 categories, the immune system process was most significantly over-represented (z-score, 20.63). This indicates that a group of genes, which are functionally related to immune system, were over-represented in the list of the differentially expressed genes identified above. This is consistent with the previously known functions of annexin A1 in immune system [@pone.0043551-Perretti1], thus the other genes related to immune system changed their expression levels in the tumors grown in the host microenvironment where annexin A1 was knocked out. Breakdown of this immune system process into its subcategories is shown in detail with the biological processes down levels by levels ([Fig.S1](#pone.0043551.s001){ref-type="supplementary-material"}) and shown in summary with representative biological processes ([Fig. 3](#pone-0043551-g003){ref-type="fig"}). The process of immune response to tumor cell was not much different between tumors in annexin A1 ko and wild-type conditions, consistent with our notion that it was the tumor stroma that made the tumor development significantly different in annexin A1 negative condition. Among the immune cells that were present in tumor stroma, T cell related processes stood out, which is consistent with the recently identified effects of annexin A1 on T cell functions [@pone.0043551-DAcquisto1].

![Biological process.\
The list of significantly changed genes was analyzed with Genomatix software and examined in terms of biological processes in Gene Ontology database and expressed as the Z score of a term for each biological process within the category. The higher value of Z score means more genes in that function of biological process were affected in this experiment, thus this biological process was over-represented. The Z scores for all the biological processes in top most general level of Gene Ontology structural networks of hierarchial tree of categories of biological process were shown here.](pone.0043551.g002){#pone-0043551-g002}

![Immune system process.\
Mining down in Gene Ontology structural networks of hierarchial tree of categories of biological process, from top most general biological processes in [Figure 2](#pone-0043551-g002){ref-type="fig"}, the most over-represented immune system process was further mining down levels by levels into its subcategories with all biological processes in each level shown in [Figure S1](#pone.0043551.s001){ref-type="supplementary-material"} and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in the immune system process.](pone.0043551.g003){#pone-0043551-g003}

Besides immune system process, other significantly over-represented general biological processes include cell killing, cellular process, biological adhesion, multicellular organismal process, developmental process, locomotion, response to stimulus, biological regulation, positive regulation of biological process, negative regulation of biological process, and regulation of biological process ([Fig. 2](#pone-0043551-g002){ref-type="fig"}). All of these processes were further mined down to their subcategories and the summary of the analyses were shown ([Figs. 4](#pone-0043551-g004){ref-type="fig"}, [5](#pone-0043551-g005){ref-type="fig"}, [6](#pone-0043551-g006){ref-type="fig"}, and [7](#pone-0043551-g007){ref-type="fig"}) with the detailed analyses for each subcategory shown in supplementary information section ([Figs.S2](#pone.0043551.s002){ref-type="supplementary-material"}, [S3](#pone.0043551.s003){ref-type="supplementary-material"}, [S4](#pone.0043551.s004){ref-type="supplementary-material"}, [S5](#pone.0043551.s005){ref-type="supplementary-material"}, [S6](#pone.0043551.s006){ref-type="supplementary-material"}, [S7](#pone.0043551.s007){ref-type="supplementary-material"}, and [S8](#pone.0043551.s008){ref-type="supplementary-material"}). Mining down in the cell killing process ([Fig. 4A](#pone-0043551-g004){ref-type="fig"}), again, the category T cell mediated cytotoxicity was over-represented. Further highlighting the involvement of the immune, inflammatory components in the tumor stroma, the cellular process brought out the enriched process of macrophage differentiation ([Fig. 5](#pone-0043551-g005){ref-type="fig"}). Biological adhesion process ([Fig. 4B](#pone-0043551-g004){ref-type="fig"}) showed an over-representation of leukocyte adhesion, in line with the interaction between extracellular matrix and infiltrated non-tumor cells in tumor stroma. The process of tumor necrosis factor production was over-represented ([Fig. 4C](#pone-0043551-g004){ref-type="fig"}), consistent with our previous findings of increased necrosis in tumors grown in annexin A1 null mice [@pone.0043551-Yi1], the change in tumor necrosis factor production may contribute to the amount of necrosis in tumors. As shown previously [@pone.0043551-Yi1], angiogenesis was over-represented ([Fig. 4D](#pone-0043551-g004){ref-type="fig"}), the process involving endothelial cells in tumor stroma. The locomotion process ([Fig. 4E](#pone-0043551-g004){ref-type="fig"}) indicated an over-representation of leukocyte chemotaxis and neutrophil chemotaxis, both processes involving immune cells in tumor stroma. Again in the response to stimulus process ([Fig. 6](#pone-0043551-g006){ref-type="fig"}), the categories related to inflammatory response were significantly over-represented. It is noteworthy that the acute inflammatory response was also over-represented but not the chronic inflammatory response. Finally, biological processes related to regulation ([Fig. 7](#pone-0043551-g007){ref-type="fig"}), with overlapping subcategories showed a general over-representation of regulation for those over-represented biological processes discussed above. The positive regulation of biological process was more over-represented than the negative regulation of biological process.

![General biological processes other than immune system process.\
(A) Cell killing. (B) Biological adhesion. (C) Multicellular organismal process. (D) Developmental process. (E) Locomotion. Similarly as [Figure 3](#pone-0043551-g003){ref-type="fig"}, the most general processes were further mining down levels by levels into its subcategories with all biological processes in each level shown in [Figures S2](#pone.0043551.s002){ref-type="supplementary-material"}, [S3](#pone.0043551.s003){ref-type="supplementary-material"}, [S4](#pone.0043551.s004){ref-type="supplementary-material"}, [S5](#pone.0043551.s005){ref-type="supplementary-material"}, and [S6](#pone.0043551.s006){ref-type="supplementary-material"} and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in these biological processes.](pone.0043551.g004){#pone-0043551-g004}

![Cellular process.\
Similarly, from [Figure 2](#pone-0043551-g002){ref-type="fig"}, the cellular process was further mining down levels by levels into its subcategories with all biological processes in each level shown in [Figure S7](#pone.0043551.s007){ref-type="supplementary-material"} and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in the cellular process.](pone.0043551.g005){#pone-0043551-g005}

![Response to stimulus.\
From [Figure 2](#pone-0043551-g002){ref-type="fig"}, the response to stimulus process was further mining down levels by levels into its subcategories with all biological processes in each level shown in [Figure S8](#pone.0043551.s008){ref-type="supplementary-material"} and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in the response to stimulus process.](pone.0043551.g006){#pone-0043551-g006}

![General biological processes other than immune system process.\
(A) Biological regulation. (B) Positive regulation of biological process. (C) Negative regulation of biological process. (D) Regulation of biological process. From [Figure 2](#pone-0043551-g002){ref-type="fig"}, these biological processes were further mining down into their subcategories.](pone.0043551.g007){#pone-0043551-g007}

Furthermore, we identified the molecules that were responsible for those over-represented biological processes to reveal an interactome in tumor stroma with annexin A1 being a key functional player. Using Genomatix and IPA software, we obtained lists of biological processes or functions with a list of molecules in each process or function. We combined the lists of molecules from the processes or functions that involve various components in tumor stroma to generate the list of molecules that comprises the tumor stroma interactome which interacts with annexin A1 ([Table 1](#pone-0043551-t001){ref-type="table"}). These molecules showed most significant changes, either most down-regulated (log2 (ko/wt)\<−0.999), or most up-regulated (log2 (ko/wt)\>0.956), in the tumor stroma that lacked annexin A1. Based on the current literature data so far, most of the molecules on this list formed an interaction network built by IPA software ([Fig. 8](#pone-0043551-g008){ref-type="fig"}), of which, the interaction between annexin A1 and integrin beta 2 and the interaction between annexin A1 and vascular cell adhesion molecule 1 were identified based on current data. This interaction may occur in cell plasma membrane ([Fig. 9](#pone-0043551-g009){ref-type="fig"}). The expression ratio of integrin beta 2 in tumors from annexin A1 ko versus wt was 0.378 ([Table 1](#pone-0043551-t001){ref-type="table"}), so the integrin beta 2 was down-regulated in the absence of annexin A1; and the vascular cell adhesion molecule 1 was even down-regulated (ratio of ko versus wt was 0.214).

![Tumor stroma interactome.\
The interaction network for most of the molecules on the list in [Table 1](#pone-0043551-t001){ref-type="table"} was built by IPA software (Ingenuity company).](pone.0043551.g008){#pone-0043551-g008}

![Tumor stroma interactome sub-cellular location.\
The sub-cellular distribution of the molecules on the interaction network ([Figure 8](#pone-0043551-g008){ref-type="fig"}) was built by IPA software (Ingenuity company).](pone.0043551.g009){#pone-0043551-g009}
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###### Tumor Stroma Interactome for Annexin A1.

![](pone.0043551.t001){#pone-0043551-t001-1}

  Gene Symbol                                            Gene Name/Gene Title                                            Entrez Gene   ko/wt
  ------------- ------------------------------------------------------------------------------------------------------- ------------- -------
  Igh-6                                    immunoglobulin heavy chain 6 (heavy chain of IgM)                                16019      0.065
  Tgfbi                                        transforming growth factor, beta induced                                     21810      0.108
  H2-Eb1                                     histocompatibility 2, class II antigen E beta                                  14969      0.124
  Cd74           CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)      16149      0.143
  Ptprc                                     protein tyrosine phosphatase, receptor type, C                                  19264      0.143
  Mmp13                                               matrix metallopeptidase 13                                            17386      0.147
  Pla2g7                   phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)                 27226      0.164
  H2-Aa                                     histocompatibility 2, class II antigen A, alpha                                 14960      0.169
  Cxcl13                                           chemokine (C-X-C motif) ligand 13                                        55985      0.170
  H2-Ab1                                   histocompatibility 2, class II antigen A, beta 1                                 14961      0.199
  Fpr-rs2                                     formyl peptide receptor, related sequence 2                                   14289      0.203
  Mmp3                                                 matrix metallopeptidase 3                                            17392      0.206
  Sfrp2                                           secreted frizzled-related protein 2                                       20319      0.206
  Vcam1                                            vascular cell adhesion molecule 1                                        22329      0.214
  Tgm2                                             transglutaminase 2, C polypeptide                                        21817      0.227
  H2-Q7                                         histocompatibility 2, Q region locus 7                                    100044020    0.227
  Ly6a                                           lymphocyte antigen 6 complex, locus A                                     110454      0.230
  Ly86                                                   lymphocyte antigen 86                                              17084      0.234
  Igj                                                immunoglobulin joining chain                                           16069      0.237
  Fcgr1                                            Fc receptor, IgG, high affinity I                                        14129      0.238
  H2-DMa                                       histocompatibility 2, class II, locus DMa                                    14998      0.241
  C1qb                                 complement component 1, q subcomponent, beta polypeptide                             12260      0.244
  C1qc                                      complement component 1, q subcomponent, C chain                                 12262      0.250
  Hck                                                   hemopoietic cell kinase                                             15162      0.256
  Saa3                                                     serum amyloid A 3                                                20210      0.257
  Bcl2a1d                                   B-cell leukemia/lymphoma 2 related protein A1d                                  12047      0.258
  Bcl2a1a                                   B-cell leukemia/lymphoma 2 related protein A1a                                  12044      0.258
  Ccr5                                             chemokine (C-C motif) receptor 5                                         12774      0.261
  Col1a1                                             procollagen, type I, alpha 1                                           12842      0.268
  Cxcl16                                           chemokine (C-X-C motif) ligand 16                                        66102      0.271
  Il2rg                                           interleukin 2 receptor, gamma chain                                       16186      0.281
  C1qa                                 complement component 1, q subcomponent, alpha polypeptide                            12259      0.288
  Cxcl9                                            chemokine (C-X-C motif) ligand 9                                         17329      0.290
  Ccl8                                              chemokine (C-C motif) ligand 8                                        100048554    0.290
  Lpl                                                     lipoprotein lipase                                                16956      0.291
  Klra17                               killer cell lectin-like receptor, subfamily A, member 17                            170733      0.291
  Egr1                                                  early growth response 1                                             13653      0.296
  Csf1r                                          colony stimulating factor 1 receptor                                       12978      0.297
  Ctss                                                        cathepsin S                                                   13040      0.300
  Itgax                                                    integrin alpha X                                                 16411      0.301
  Coro1a                                           coronin, actin binding protein 1A                                        12721      0.301
  Clec7a                                        C-type lectin domain family 7, member a                                     56644      0.301
  Fcer1g                                 Fc receptor, IgE, high affinity I, gamma polypeptide                               14127      0.308
  Lcp2                                              lymphocyte cytosolic protein 2                                          16822      0.311
  Tnc                                                         tenascin C                                                    21923      0.319
  Irf8                                              interferon regulatory factor 8                                          15900      0.319
  Srgn                                                         serglycin                                                    19073      0.322
  Serpina3n                          serine (or cysteine) peptidase inhibitor, clade A, member 3N                           20716      0.325
  Tyrobp                                     TYRO protein tyrosine kinase binding protein                                   22177      0.327
  Ccl3                                              chemokine (C-C motif) ligand 3                                          20302      0.336
  Cd53                                                       CD53 antigen                                                   12508      0.342
  Cd48                                                       CD48 antigen                                                   12506      0.346
  Fyb                                                     FYN binding protein                                               23880      0.352
  Ccl5                                              chemokine (C-C motif) ligand 5                                          20304      0.357
  Fcgr3                                           Fc receptor, IgG, low affinity III                                        14131      0.365
  Lox                                                        lysyl oxidase                                                  16948      0.365
  Cxcl3                                            chemokinne (C-X-C motif) ligand 3                                       330122      0.369
  C3ar1                                           complement component 3a receptor 1                                        12267      0.369
  Slc11a1                 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1               18173      0.374
  Cxcr4                                           chemokine (C-X-C motif) receptor 4                                        12767      0.377
  Thbs1                                                    thrombospondin 1                                                640441      0.378
  Itgb2                                                     integrin beta 2                                                 16414      0.378
  Serping1                            serine (or cysteine) peptidase inhibitor, clade G, member 1                           12258      0.381
  Cd24a                                                      CD24a antigen                                                  12484      0.382
  Itgam                                                    integrin alpha M                                                 16409      0.386
  Pdgfra                              platelet derived growth factor receptor, alpha polypeptide                            18595      0.392
  Cxcl2                                            chemokine (C-X-C motif) ligand 2                                         20310      0.392
  Il12rb1                                           interleukin 12 receptor, beta 1                                         16161      0.397
  Hba-a2                                            hemoglobin alpha, adult chain 2                                         15122      0.407
  Hba-a1                                            hemoglobin alpha, adult chain 1                                        110257      0.407
  Serpine1                            serine (or cysteine) peptidase inhibitor, clade E, member 1                           18787      0.412
  Ikzf1                                               IKAROS family zinc finger 1                                           22778      0.412
  C3                                                    complement component 3                                              12266      0.414
  Dcn                                                           decorin                                                     13179      0.415
  S100a6                                      S100 calcium binding protein A6 (calcyclin)                                   20200      0.429
  Stat1                                   signal transducer and activator of transcription 1                                20846      0.434
  Psmb8                proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7)             16913      0.441
  Lair1                                         leukocyte-associated Ig-like receptor 1                                     52855      0.442
  Cxcl4                                            chemokine (C-X-C motif) ligand 4                                         56744      0.443
  Il2rg                                           interleukin 2 receptor, gamma chain                                       16186      0.444
  Wisp1                                       WNT1 inducible signaling pathway protein 1                                    22402      0.444
  Rarres2                               retinoic acid receptor responder (tazarotene induced) 2                             71660      0.448
  S100a9                                    S100 calcium binding protein A9 (calgranulin B)                                 20202      0.451
  Hcls1                                       hematopoietic cell specific Lyn substrate 1                                   15163      0.452
  Cxcl10                                           chemokine (C-X-C motif) ligand 10                                      100045000    0.453
  Lyn                                     Yamaguchi sarcoma viral (v-yes-1) oncogene homolog                               676654      0.454
  Ccr1                                             chemokine (C-C motif) receptor 1                                         12768      0.455
  Klrd1                                 killer cell lectin-like receptor, subfamily D, member 1                             16643      0.455
  Csf2rb                   colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)                12983      0.456
  Selplg                                         selectin, platelet (p-selectin)ligand                                      20345      0.457
  Pltp                                               phospholipid transfer protein                                          18830      0.457
  Serpina1a                          serine (or cysteine) peptidase inhibitor, clade A, member 1a                           20700      0.459
  S100a8                                    S100 calcium binding protein A8 (calgranulin A)                                 20201      0.460
  Dock2                                               dedicator of cyto-kinesis 2                                           94176      0.462
  Itgb5                                                     integrin beta 5                                                 16419      0.462
  Thy1                                               thymus cell antigen 1, theta                                           21838      0.465
  Tlr1                                                   toll-like receptor 1                                               21897      0.466
  H2-T23                                        histocompatibility 2, T region locus 23                                   100044190    0.474
  Edg3                          endothelial differentiation, sphingolipid G-protein-coupled receptor, 3                     13610      0.476
  Lilrb3               leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3           100044531    0.478
  Ctse                                                        cathepsin E                                                   13034      0.479
  Xdh                                                   xanthine dehydrogenase                                              22436      0.483
  Etv5                                                    ets variant gene 5                                               104156      0.484
  Nt5Ee                                                  5′ nucleotidase, ecto                                              23959      0.484
  SaSh3                                             SAM and SH3 domain containing 3                                         74131      0.489
  Ptger4                                       prostaglandin E receptor 4 (subtype EP4)                                     19219      0.491
  Sla                                                      src-like adaptor                                                 20491      0.492
  Bgn                                                          biglycan                                                     12111      0.494
  Psmb9                proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2)             16912      0.495
  Cfb                                                     complement factor B                                               14962      0.497
  Rac2                                           RAS-related C3 botulinum substrate 2                                       19354      0.499
  Mrc1                                                mannose receptor, C type 1                                            17533      0.500
  Cxcl12                                           chemokine (C-X-C motif) ligand 12                                        20315      0.500
  Dnm2                                                         dynamin 2                                                    13430      1.906
  Brca1                                                     breast cancer 1                                                 12189      1.917
  Dock1                                               dedicator of cyto-kinesis 1                                          330662      1.922
  Sox4                                                 SRY-box containing gene 4                                            20677      1.940
  Myh2                                    myosin, heavy polypeptide 2, skeletal muscle, adult                               17882      1.963
  Nfatc2                       nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2                    18019      1.981
  Mbp                                                    myelin basic protein                                               17196      1.986
  Scn8a                                     sodium channel, voltage-gated, type VIII, alpha                                 20273      2.019
  Lama4                                                    laminin, alpha 4                                                 16775      2.021
  Rab27a                                          RAB27A, member RAS oncogene family                                        11891      2.025
  Plxna1                                                       plexin A1                                                    18844      2.031
  Fhl1                                               four and a half LIM domains 1                                          14199      2.077
  Aplp2                                       amyloid beta (A4) precursor-like protein 2                                    11804      2.113
  Gulp1                                    GULP, engulfment adaptor PTB domain containing 1                                 70676      2.222
  Timp2                                         tissue inhibitor of metalloproteinase 2                                     21858      2.224
  Tfrc                                                   transferrin receptor                                               22042      2.967
  Cck                                                       cholecystokinin                                                 12424      3.347

While the tumor cells were originally same before being implanted into annexin A1 ko and wt mice, therefore, the tumor stroma in annexin A1 ko and wt mice exhibited significant differences in the gene expression profiles between the host body with and without annexin A1, although the genes in tumor cells may change their expression levels due to the interaction between tumor cells and the tumor stroma. Annexin A1 is abundant in neutrophils, monocytes, macrophages in wild type animal models [@pone.0043551-Perretti1]. In the annexin A1 null animal model, these non-tumor cells infiltrated into tumor stroma do not express annexin A1, this lack of annexin A1 protein function reflected as the gene expression level changes of several other proteins. This network of changes indicated these important genes/proteins ([Table 1](#pone-0043551-t001){ref-type="table"}) that are interacting with annexin A1 directly or indirectly. The interaction of annexin A1 with these proteins was previously unknown.

Discussion {#s4}
==========

Through systems biology analysis, we found this list of genes ([Table 1](#pone-0043551-t001){ref-type="table"}) that significantly changed in the tumor stroma that lacked annexin A1. This showed a mechanism that annexin A1 affects tumor development and metastasis through interaction with the various components in the microenvironment surrounding the tumor cells. Literature has also showed that these genes are associated with tumor and/or tumor stroma: IGH-6 (ko/wt = 0.065) with thymic lymphoma and lymphoblastic leukemia [@pone.0043551-Shin1]--[@pone.0043551-Nakao1], TGFBI (ko/wt = 0.108) with neuroblastoma, lung carcinoma, ovarian and prostate cancers, renal, gastrointestinal and brain tumors, colon cancer [@pone.0043551-Carn1]--[@pone.0043551-Ma1], PTPRC (ko/wt = 0.143) with human breast tumor stroma [@pone.0043551-Singer1], MMP13 (ko/wt = 0.147) with skin tumor stroma [@pone.0043551-Lederle1], CCK (ko/wt = 3.347) with human pancreatic cancer [@pone.0043551-Matters1], TFRC (ko/wt = 2.967) with colon cancer, human esophageal squamous cell carcinoma, human brain tumors, mouse mammary adenocarcinoma and rodent liver tumor [@pone.0043551-Okazaki1]--[@pone.0043551-Mizukami1], TIMP2 (ko/wt = 2.224) with human colorectal cancer, human pancreatic carcinoma, human renal cell carcinoma and human squamous cervical carcinoma [@pone.0043551-Park1]--[@pone.0043551-Anne1], BRCA1 (ko/wt = 1.917) with human breast tumor stroma [@pone.0043551-Weber1].

It is worth noting that TGFBI, as an extracellular matrix protein, has been reported differently either as a tumor suppressor [@pone.0043551-Shah1], [@pone.0043551-Zhang1] or over-expressed in tumors [@pone.0043551-Ivanov1]--[@pone.0043551-Ma1]. TGFBI was shown to promote metastasis by acting on tumor stroma [@pone.0043551-Ma1]. Here we showed that TGFBI was under-expressed in tumors from annexin A1 ko mice. In tumors grown on annexin A1 ko mice, the metastasis was reduced [@pone.0043551-Yi1]. Thus, it suggests that annexin A1 interacts with or otherwise affects TGFBI and this interaction affects the metastatic ability of tumors. In addition, loss of TGFBI can induce resistance to chemotherapeutic agent paclitaxel in ovarian cancer cells [@pone.0043551-Ahmed2], while human tumor cells with over-expressed levels of TGFBI showed an increased sensitivity to etoposide, paclitaxel, cisplatin and gemcitabine [@pone.0043551-Irigoyen1]. Similarly, stroma-derived annexin A1 has been shown to play a role in γ-irradiation-induced T-cell lymphoblastic lymphoma development, with annexin A1 being a candidate resistance gene against γ-radiation exposure [@pone.0043551-Santos1]. It has been reviewed that the cellular and non-cellular components of the tumor microenvironment contribute to the chemoresistance [@pone.0043551-Sebens1]. Therefore, annexin A1 and TGFBI may be further studied together to elicit a mechanism for drug resistance. Annexin A1 and TGFBI could be important therapy targets to manipulate to improve the efficacy of radio-and chemo-therapies for cancer patients, to reduce resistance to treatments and decrease recurrence of cancer.

Protein tyrosine phosphatase gene expression was shown to be up-regulated in stromal fibroblasts from human breast tumors [@pone.0043551-Singer1], while our study showed PTPRC down-regulated in tumor stroma without annexin A1 ([Table 1](#pone-0043551-t001){ref-type="table"}), this suggests that inhibiting annexin A1 may disrupt tumor stroma to hamper tumor progression via decreasing expression level of protein tyrosine phosphatase. MMP13 was shown to promote angiogenesis [@pone.0043551-Lederle1], which is consistent with the finding in this study of down-regulated MMP13 expression ([Table 1](#pone-0043551-t001){ref-type="table"}) and impaired tumor growth and angiogenesis in tumors on annexin A1 knockout mice [@pone.0043551-Yi1].

The role of endogenous cholecystokinin (CCK) in human pancreatic cancer is not clear. The pancreatic cancer cells produced both CCK and gastrin, however the CCK level was lower than the gastrin. It seemed gastrin played a more dominant role than CCK in stimulating tumor growth. While down-regulation of gastrin inhibited growth of pancreatic tumor, change in the CCK level did not affect the tumor growth [@pone.0043551-Matters1]. Here we showed a huge increase of CCK mRNA expression in tumors from annexin A1 ko mice, the further study of interaction of annexin A1 and CCK will shed light on understanding the role of CCK in human cancers.

Also, this study showed a possible interaction between annexin A1 and BRCA1. It has been shown that in the breast cancers containing mutated BRCA1, a common breast cancer susceptibility gene, changes in the tumor stroma facilitate the malignant transformation of the tumor cells [@pone.0043551-Weber2]. BRCA1 is also believed to be a regulator in mammary stem cell differentiation and associated with cancer stem cells. One of the identified markers for selection of human stem cells and cancer stem cells is aldehyde dehydrogenase 1 (ALDH1), however, the exact function of ALDH1 in stem cells is still mostly unknown. ALDH1 expression is significantly increased in both tumor cells and tumor stroma in breast cancers carrying BRCA1 mutations [@pone.0043551-HeermavanVoss1]. The cancer stem cells possess tumor initiating capacity and therapy resistance. Therefore, consistent with the above mentioned annexin A1 being candidate resistance gene, an association between annexin A1 and stem cells and cancer stem cells is strongly possible and worth further investigation to help understand the exact functions of stem cell markers.
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###### 

**Breakdown of immune system process category into its subcategories.** (A) Immune system process. (B1) Immune response. (B2) Leukocyte activation. (B3) Immune system development. (C1) Lymphocyte activation. (C2) Myeloid leukocyte activation. (C3) Regulation of leukocyte activation. (C4) Hemopoietic or lymphoid organ development. (D) Hemopoiesis. (E) Leukocyte differentiation. (F) Lymphocyte differentiation. Mining down in Gene Ontology structural networks of hierarchial tree of categories of biological process, the top level category, immune system process, labeled (A), was further mining down levels by levels into its subcategories with all biological processes in each category shown here, labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here.

(PPT)

###### 

Click here for additional data file.

###### 

**Breakdown of cell killing category into its subcategories.** (A) Cell killing. (B) Leukocyte mediated cytotoxicity. (C) T cell mediated cytotoxicity. (D) Regulation of T cell mediated cytotoxicity. Similarly as [Figure S1](#pone.0043551.s001){ref-type="supplementary-material"}, the top level category, cell killing, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here.

(PPT)

###### 

Click here for additional data file.

###### 

**Breakdown of biological adhesion category into its subcategories.** (A) Biological adhesion. (B) Cell adhesion. (C1) Cell-cell adhesion. (C2) Cell-substrate adhesion. (C3) Regulation of cell adhesion. (C4) Positive regulation of cell adhesion. (C5) Negative regulation of cell adhesion. (D1) Leukocyte adhesion. (D2) Regulation of cell-substrate adhesion. (D3) Regulation of cell-cell adhesion. (D4) Regulation of cell adhesion mediated by integrin. (E1) Positive regulation of cell adhesion mediated by integrin. (E2) Regulation of cell-cell adhesion mediated by integrin. Similarly as [Figure S1](#pone.0043551.s001){ref-type="supplementary-material"}, the top level category, biological adhesion, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here.

(PPT)

###### 

Click here for additional data file.

###### 

**Breakdown of multicellular organismal process category into its subcategories.** (A) Multicellular organismal process. (B1) Cytokine production. (B2) System process. (B3) Multicellular organismal development. (B4) Tissue remodeling. (B5) Multicellular organismal homeostasis. (B6) Regulation of body fluid levels. (B7) Regulation of multicellular organismal process. (C1) Tumor necrosis factor production. (C2) System development. (C3) Negative regulation of tissue remodeling. (C4) Regulation of tissue remodeling. (C5) Regulation of angiogenesis. (D) Regulation of tumor necrosis factor production. (E) Regulation of tumor necrosis factor biosynthetic process. Similarly as [Figure S1](#pone.0043551.s001){ref-type="supplementary-material"}, the top level category, multicellular organismal process, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here.

(PPT)

###### 

Click here for additional data file.

###### 

**Breakdown of developmental process category into its subcategories.** (A) Developmental process. (B1) Multicellular organismal development. (B2) Anatomical structure morphogenesis. (B3) Anatomical structure formation. (B4) Anatomical structure development. (B5) Cellular developmental process. (B6) Regulation of developmental process. (B7) Negative regulation of developmental process. (B8) Positive regulation of developmental process. (C) Positive regulation of programmed cell death. (D1) Induction of programmed cell death. (D2) Positive Regulation of apoptosis. (E1) Induction of apoptosis. (E2) Positive regulation of lymphocyte apoptosis. (F1) Induction of apoptosis by extracellular signals. (F2) Induction of apoptosis by intracellular signals. Similarly as [Figure S1](#pone.0043551.s001){ref-type="supplementary-material"}, the top level category, developmental process, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here.

(PPT)

###### 

Click here for additional data file.

###### 

**Breakdown of locomotion category into its subcategories.** (A) Locomotion. (B1) Taxis. (B2) Regulation of locomotion. (B3) Cell motility. (C) Chemotaxis. (D) Cell chemotaxis. (E) Leukocyte chemotaxis. Similarly as [Figure S1](#pone.0043551.s001){ref-type="supplementary-material"}, the top level category, locomotion, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here.

(PPT)

###### 

Click here for additional data file.

###### 

**Breakdown of cellular process category into its subcategories.** (A) Cellular process. (B1) Cell activation. (B2) Cell motion. (B3) Cell communication. (B4) Cell adhesion. (B5) Cell proliferation. (B6) Cellular component organization. (B7) Cellular developmental process. (C1) Mononuclear cell proliferation. (C2) Cell differentiation. (D1) Lymphocyte proliferation. (D2) Leukocyte differentiation. (E) Myeloid leukocyte differentiation. Similarly as [Figure S1](#pone.0043551.s001){ref-type="supplementary-material"}, the top level category, cellular process, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here.

(PPT)

###### 

Click here for additional data file.

###### 

**Breakdown of response to stimulus category into its subcategories.** (A) Response to stimulus. (B1) Response to external stimulus. (B2) Response to stress. (C1) Defense response. (C2) Response to wounding. (C3) Taxis. (D1) Inflammatory response. (D2) Chemotaxis. (E) Acute inflammatory response. (F) Activation of plasma proteins during acute inflammatory response. (G) Complement activation. Similarly as [Figure S1](#pone.0043551.s001){ref-type="supplementary-material"}, the top level category, response to stimulus, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here.

(PPT)

###### 

Click here for additional data file.
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